Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?-Reference-Cited by-同舟云学术

Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?

Published:2019-12-06 Issue:3 Volume:30 Page:1601-1608
ISSN:0938-7994
Container-title:European Radiology
language:en
Short-container-title:Eur Radiol

Author:

Luedemann Willie Magnus,Geisel Dominik,Gebauer Bernhard,Schnapauff Dirk,Chapiro Julius,Wieners Gero,Steffen Ingo,Kahn Johannes

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00330-019-06430-2.pdf

Reference25 articles.

1. Center MM, Jemal A (2011) International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev 20:2362–2368

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108

3. Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391:1301–1314

4. Liver and Intrahepatic Bile Duct Cancer - Cancer Stat Facts. In: SEER. Available via https://seer.cancer.gov/statfacts/html/livibd.html. Accessed 4 Mar 2019

5. Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC;Frontiers in Oncology;2022-10-28

2. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI;Radiology;2022-07

3. The Diagnostic Value of Contrast-Enhanced Ultrasound and Enhanced CT Combined with Tumor Markers AFP and CA199 in Liver Cancer;Journal of Healthcare Engineering;2022-02-21

4. Integrated Liver Inflammatory Score Predicts the Therapeutic Outcome of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization;Journal of Vascular and Interventional Radiology;2021-08

5. Systemic Inflammation Response Index is a Prognostic Risk Factor in Patients with Hepatocellular Carcinoma Undergoing TACE;Risk Management and Healthcare Policy;2021-06